

# World Journal of *Clinical Cases*

*World J Clin Cases* 2018 October 26; 6(12): 483-576





**REVIEW**

- 483 Cancer and comorbidity: The role of leptin in breast cancer and associated pathologies  
*Ray A*
- 493 One more chance of fistula healing in inflammatory bowel disease: Stem cell therapy  
*Turse EP, Dailey FE, Naseer M, Partyka EK, Tahan, V*
- 501 Treat-to-target in Crohn's disease: Will transmural healing become a therapeutic endpoint?  
*Serban DE*

**ORIGINAL ARTICLE**

**Basic Study**

- 514 CYP2C19 polymorphism has no influence on rabeprazole-based hybrid therapy for *Helicobacter pylori* eradication  
*Lin TJ, Lee HC, Lin CL, Wang CK, Chen KY, Wu DC*

**Retrospective Study**

- 521 Declining diagnostic accuracy of non-invasive fibrosis tests is associated with elevated alanine aminotransferase in chronic hepatitis B  
*Wang L, Fan YX, Dou XG*

**CASE REPORT**

- 531 Gemcitabine-induced haemolytic uremic syndrome, although infrequent, can it be prevented: A case report and review of literature  
*Cidon EU, Martinez PA, Hickish T*
- 538 Colovesical fistula as the initial manifestation of advanced colon cancer: A case report and review of literature  
*Skierucha M, Barud W, Baraniak J, Krupski W*
- 542 Robotic transoral vestibular parathyroidectomy: Two case reports and review of literature  
*Ozdenkaya Y, Ersavas C, Arslan NC*
- 548 Atypical lipomatous tumor in the ligamentum teres of liver: A case report and review of the literature  
*Usuda D, Takeshima K, Sangen R, Nakamura K, Hayashi K, Okamura H, Kawai Y, Kasamaki Y, Inuma Y, Saito H, Kanda T, Urashima S*



- 554** Computed tomography and magnetic resonance imaging findings of metastatic rectal linitis plastica from prostate cancer: A case report and review of literature  
*You JH, Song JS, Jang KY, Lee MR*
- 559** Live birth after hysteroscopy performed inadvertently during early pregnancy: A case report and review of literature  
*Zhao CY, Ye F*
- 564** Mesh migration into the sigmoid colon after inguinal hernia repair presenting as a colonic polyp: A case report and review of literature  
*Liu S, Zhou XX, Li L, Yu MS, Zhang H, Zhong WX, Ji F*
- 570** *CNKSR2* mutation causes the X-linked epilepsy-aphasia syndrome: A case report and review of literature  
*Sun Y, Liu YD, Xu ZF, Kong QX, Wang YL*

**ABOUT COVER**

Editorial Board Member of *World Journal of Clinical Cases*, Ashu Seith Bhalla, MD, Professor, Department of Radiodiagnosis, All India Institute of Medical Sciences, New Delhi 110029, India

**AIM AND SCOPE**

*World Journal of Clinical Cases* (*World J Clin Cases*, *WJCC*, online ISSN 2307-8960, DOI: 10.12998) is a peer-reviewed open access academic journal that aims to guide clinical practice and improve diagnostic and therapeutic skills of clinicians.

The primary task of *WJCC* is to rapidly publish high-quality Autobiography, Case Report, Clinical Case Conference (Clinicopathological Conference), Clinical Management, Diagnostic Advances, Editorial, Field of Vision, Frontier, Medical Ethics, Original Articles, Clinical Practice, Meta-Analysis, Minireviews, Review, Therapeutics Advances, and Topic Highlight, in the fields of allergy, anesthesiology, cardiac medicine, clinical genetics, clinical neurology, critical care, dentistry, dermatology, emergency medicine, endocrinology, family medicine, gastroenterology and hepatology, geriatrics and gerontology, hematology, immunology, infectious diseases, internal medicine, obstetrics and gynecology, oncology, ophthalmology, orthopedics, otolaryngology, pathology, pediatrics, peripheral vascular disease, psychiatry, radiology, rehabilitation, respiratory medicine, rheumatology, surgery, toxicology, transplantation, and urology and nephrology.

**INDEXING/ABSTRACTING**

*World Journal of Clinical Cases* (*WJCC*) is now indexed in PubMed, PubMed Central, Science Citation Index Expanded (also known as SciSearch®), and Journal Citation Reports/Science Edition. The 2018 Edition of Journal Citation Reports cites the 2017 impact factor for *WJCC* as 1.931 (5-year impact factor: N/A), ranking *WJCC* as 60 among 154 journals in Medicine, General and Internal (quartile in category Q2).

**EDITORS FOR THIS ISSUE**

**Responsible Assistant Editor:** *Xiang Li*  
**Responsible Electronic Editor:** *Wen-Wen Tan*  
**Proofing Editor-in-Chief:** *Lian-Sheng Ma*

**Responsible Science Editor:** *Fang-Fang Ji*  
**Proofing Editorial Office Director:** *Jin-Lei Wang*

**NAME OF JOURNAL**  
*World Journal of Clinical Cases*

**ISSN**  
ISSN 2307-8960 (online)

**LAUNCH DATE**  
April 16, 2013

**FREQUENCY**  
Semimonthly

**EDITORS-IN-CHIEF**  
**Sandro Vento, MD**, Department of Internal Medicine, University of Botswana, Private Bag 00713, Gaborone, Botswana

**EDITORIAL BOARD MEMBERS**  
All editorial board members resources online at <http://www.wjgnet.com/2307-8960/editorialboard.htm>

**EDITORIAL OFFICE**  
Jin-Lei Wang, Director

*World Journal of Clinical Cases*  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [editorialoffice@wjgnet.com](mailto:editorialoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLISHER**  
Baishideng Publishing Group Inc  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-2238242  
Fax: +1-925-2238243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

**PUBLICATION DATE**  
October 26, 2018

**COPYRIGHT**

© 2018 Baishideng Publishing Group Inc. Articles published by this Open Access journal are distributed under the terms of the Creative Commons Attribution Non-commercial License, which permits use, distribution, and reproduction in any medium, provided the original work is properly cited, the use is non commercial and is otherwise in compliance with the license.

**SPECIAL STATEMENT**

All articles published in journals owned by the Baishideng Publishing Group (BPG) represent the views and opinions of their authors, and not the views, opinions or policies of the BPG, except where otherwise explicitly indicated.

**INSTRUCTIONS TO AUTHORS**

<http://www.wjgnet.com/bpg/gerinfo/204>

**ONLINE SUBMISSION**

<http://www.f6publishing.com>

## CNKS2 mutation causes the X-linked epilepsy-aphasia syndrome: A case report and review of literature

Ying Sun, Yi-Dan Liu, Zhi-Feng Xu, Qing-Xia Kong, Yan-Ling Wang

Ying Sun, Yi-Dan Liu, Cheeloo College of Medicine, Shandong University, Jinan 250012, Shandong Province, China

Zhi-Feng Xu, First Hospital of Handan, Handan 056002, Hebei Province, China

Qing-Xia Kong, Yan-Ling Wang, Department of Neurology, Affiliated Hospital of Jining Medical University, Jining 272000, Shandong Province, China

ORCID number: Ying Sun (0000-0001-5585-671X); Yi-Dan Liu (0000-0001-8470-4512); Zhi-Feng Xu (0000-0002-3801-8666); Qing-Xia Kong (0000-0003-3803-5789); Yan-Ling Wang (0000-0002-3429-0208).

**Author contributions:** Kong QX and Wang YL designed the study and wrote the manuscript; Sun Y, Liu YD and Xu ZF collected the clinical data and edited the manuscript.

**Supported by** Jining Medical University, No. JYP201740.

**Informed consent statement:** The patient involved in this study gave his written informed consent authorizing use and disclosure of his protected health information.

**Conflict-of-interest statement:** All authors have declared no competing interests exist.

**CARE Checklist (2013) statement:** The authors have read the CARE Checklist (2013), and the manuscript was prepared and revised according to the CARE Checklist (2013).

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: <http://creativecommons.org/licenses/by-nc/4.0/>

**Manuscript source:** Unsolicited manuscript

**Correspondence to:** Qing-Xia Kong, MD, PhD, Chief Doctor,

Department of Neurology, Affiliated Hospital of Jining Medical University, Guhuai Road No. 89, Jining 272000, Shandong Province, China. [kxdqy8@sohu.com](mailto:kxdqy8@sohu.com)  
Telephone: +86-18678766805  
Fax: +86-537-2213030

**Received:** July 2, 2018

**Peer-review started:** July 2, 2018

**First decision:** July 29, 2018

**Revised:** August 21, 2018

**Accepted:** August 28, 2018

**Article in press:** August 28, 2018

**Published online:** October 26, 2018

### Abstract

The mutation in *CNKS2* leads to a broad spectrum of phenotypic variability and manifests as an X-linked intellectual disability. However, we reported that the male patient in this study not only had intellectual disability but also epileptic seizures. In addition, there were progressive language impairment, attention deficit hyperactivity disorder and autism. Electroencephalograms showed continuous spike-and-wave during sleep. Genetic testing revealed a *de novo* mutation of the *CNKS2* gene (*c.2185C>T, p.Arg729Ter*) in the child that was not detected in the parents. Therefore, the child was diagnosed with X-linked epilepsy aphasia syndrome. Deletion of the *CNKS2* gene has been rarely reported in epilepsy aphasia syndrome, but no *de novo* mutation has been found in this gene. This report not only adds to the spectrum of epilepsy aphasia syndrome but also helps clinicians in diagnosis and genetic counseling.

**Key words:** Epilepsy; Language impairment; Mental retardation; *De novo* mutation of *CNKS2*; X-linked epilepsy-aphasia syndrome

© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved.



**Core tip:** Patient with epileptic seizures and progressive language impairment. Genetic testing revealed a *de novo* mutation of the *CNKSR2* gene in the child and was not detected in the parents. Therefore, the gene may lead to X-linked epilepsy aphasia syndrome.

Sun Y, Liu YD, Xu ZF, Kong QX, Wang YL. *CNKSR2* mutation causes the X-linked epilepsy-aphasia syndrome: A case report and review of literature. *World J Clin Cases* 2018; 6(12): 570-576 Available from: URL: <http://www.wjgnet.com/2307-8960/full/v6/i12/570.htm> DOI: <http://dx.doi.org/10.12998/wjcc.v6.i12.570>

## INTRODUCTION

Atypical epilepsy-aphasia syndrome is caused by Landau-Kleffner syndrome (LKS) and epileptic encephalopathy, with a continuous spike-and-wave pattern during sleep<sup>[1]</sup>. The synapse is the core component of brain operations and executive functions, and its function plays an important role in brain neuron function<sup>[2]</sup>. *CNKSR2* is located on the X chromosome, and as a synaptic protein, it is involved in RAS/MAPK signal transduction<sup>[3]</sup>. It is highly expressed in the brain<sup>[4]</sup>, and its mutation or deletion causes a wide range of neurodevelopmental defects<sup>[5]</sup>. Currently, *CNKSR2* deletion or mutation has been shown to induce symptoms that are part of the EAS spectrum<sup>[6-9]</sup>. In this paper, we review clinical data and genetic test results of a child with epilepsy and aphasia and have identified a *de novo* mutation: *CNKSR2* (c.2185C>T, p.Arg729Ter). We reviewed the literature and analyzed the clinical features of X-linked epilepsy-aphasia syndrome in order to assist clinicians in their diagnosis of this condition and to help provide genetic counseling.

## CASE REPORT

An 8-year and 8-mo-old boy from China was admitted to the hospital due to paroxysmal unconsciousness for more than 6 years. The performance of paroxysmal loss of consciousness was associated with brief jerks of the limbs, eye staring, lip bruising, spitting foam from the mouth, and sometimes with urinary incontinence; however, fever was absent. Each episode lasted 2-3 min and resolved on its own. The episodes of epileptic seizures occurred in varying lengths of times; sometimes, the episodes occurred once every six months, and sometimes only once a month. The form of each seizure was similar.

During the clinical examination, the child did not have any abnormal physical signs. There was no abnormal language expression before epileptic episodes. After the onset of a seizure, he gradually showed signs of poor language expression, repeated speech, unanswerable questions, uncooperative actions, and attention deficit hyperactivity disorder (ADHD). The child had intellectual

disability, childish behavior, poor communication skills with the outside world, and autism performance. Parents were healthy and involved in a nonconsanguineous marriage, and family history was not significantly abnormal. Maternal pregnancy was normal, and perinatal history of hypoxia and asphyxia was denied. The Apgar score was unknown.

Auxiliary check: There were no abnormalities in routine laboratory examinations, ultrasonography or craniocerebral MRI. His video-electroencephalogram (EEG) (Figure 1) results showed an abnormal EEG and supported the diagnosis of epilepsy.

## Gene detection

Two milliliter of peripheral venous blood was extracted from the patient and her parents. Genomic DNA from the patient was extracted from blood using standard methods for whole exome sequencing. Mutation of *CNKSR2* gene was found in the children. Primers were designed based on the gene tested (chrX:21627228). The parents used Sanger sequencing after PCR to analyze the coding exons and flanking introns of the *CNKSR2* gene (NM\_014927). The established variant was sequenced in both forward (AGTCCCCAAGCCCAAGCTAC) and reverse directions (ACTGGCTGTCTTGCGAATGG). A nucleotide variation of c.2185C>T (code no. 2185 nucleotides changed from C to T) was identified in the patient's *CNKSR2* gene. The mutation altered the codon sequence of the amino acid Arg into a termination codon (p.Arg729Ter). No abnormalities were identified at this site in the parents. The mutation was *de novo* (Figure 2). The child was eventually diagnosed with X-Linked EAS, and was treated with hormone and anti-epileptic drugs (Sodium valproate, Levetiracetan). After these treatments, his seizures had eased.

To highlight changes in the secondary structure of the *CNKSR2* gene, we used the more popular PSIPRED (<http://bioinf.cs.ucl.ac.uk/psipred/>)<sup>[10]</sup> for structural prediction. The codon of no. 729 amino acid Arg was altered into a termination codon (p.Arg729Ter), resulting in the inability to express the 729-1034 sequence of amino acids (Figure 3). RaptorX (<http://raptorx.uchicago.edu>)<sup>[11-13]</sup> can predict protein tertiary structures. After inputting the sequence, the 3D structure of the protein sequence can be predicted from the protein database (PDB) (Figure 4). Compared with the wild type, the patient's *CNKSR2* gene did not fold completely in its spatial structure, thus affecting protein function.

## DISCUSSION

*CNKSR2* (also known as *CNK2*, *KSR2*, *MAGUIN*)<sup>[8]</sup> interacts with synaptic scaffold molecules (S-SCAM) and the postsynaptic density (PSD)-95/synaptic-associated protein (SAP) 90 to form a complex<sup>[14]</sup>. The complex is involved in RAS/MAPK signaling and mediates neuronal proliferation, migration, differentiation and death, as well as RAS-mediated synapse formation<sup>[5-9]</sup>. It also connects




**Figure 1 Electroencephalogram of the patient.** It showed generalized continuous spike-and-wave patterns in the bitemporal and frontal lobes, noticeable on the left side. Abnormal discharge was more pronounced during the sleep-electroencephalogram. Slower on background activity.

ts N-methyl-D-aspartate (NMDA) receptors to neuronal cell adhesion molecules<sup>[14]</sup>. The NMDA subunit encoded by *GRIN2A* is the first gene associated with EAS<sup>[2]</sup>. *GRIN2A* mutations reduce NMDA receptor trafficking and agonist potency–molecular profiling as well as functional rescue<sup>[15]</sup>. *GRIN2A* gene is a rare causative gene in Chinese patients with EAS, suggesting the possibility of other genes being involved in the pathogenesis<sup>[16]</sup>. Hence, we speculate that a mutation or deletion of *CNKS2* may result in changes to the NMDA receptor activity and might affect downstream signaling cascades. Abnormal NMDA receptor will potentially damage the cortical thalamus network during sleep<sup>[17]</sup>. *CNKS2* is highly expressed in the brain (especially in the hippocampus, amygdala, and cerebellum), and mutations result in loss of specificity and might also affect brain function<sup>[7]</sup>, leading to seizures and neurodevelopmental disorders that especially affect the patient's speech expression<sup>[2]</sup>. *CNKS2* is a gene located on the X chromosome, and its mutations or deletions lead to X linkage intelligence disorder (XLID)<sup>[8]</sup>. The main features of XLID are: (1) intellectual disability; (2) highly restrictive speech (especially expression of language); (3) ADHD; (4) transient childhood epilepsy; and (5) epilepsy with continuous spike waves of slow-wave sleep (CSWS) in early childhood<sup>[5]</sup>.

Before experiencing seizures, our patient suffered from developmental delays and ADHD, which is consistent with the performance of X-linked intellectual disability. After seizure occurrence, the patients' speech expression gradually decreased, the EEG continued to show abnormal wave patterns during sleep, and a *de novo* mutation of the *CNKS2* gene was identified. Therefore, we diagnosed this patient as X-linked epilepsy-aphasia syndrome. After definite diagnosis, patients were given immunoglobulin (400-500 mg/kg per day, 3-5 d for

1 course) and oral prednisone (from 1-3 mg/kg per day, and after one month, changed to 1 mg/kg per day), with a total course of 6 to 12 mo. Meanwhile, lamotrigine (75 mg/qd) and sodium valproate oral solution (6 mL/bid) were continued for antiepileptic treatment. At telephone follow-up one year later, the child had fewer epileptic seizures than before as well as partial improvement in verbal ability and an ability to repeat speech; however, the patient had no improvement in intelligence. The disease duration was more than 6 years. If diagnosed early and actively treated, the patient's intelligence, seizures, and language may have been better mitigated.

The underlying mechanism for EAS disorders occurrence remains unknown, although environmental factors such as thalamic injury<sup>[18]</sup> and immunity disorders<sup>[19]</sup>, with evidence of onconeural antibodies that can cause the EEG phenotype, have been reported. Studies have shown that the antibodies of brain endothelial cells and nuclei in children were elevated<sup>[20]</sup>. Additionally, inflammatory markers of children with electrical status epilepticus in sleep (ESES) may be increased<sup>[21]</sup>. Some researchers have proposed a potential autoimmune reaction secondary to blood-brain-barrier disruption from a thalamocortical uncoupling secondary to the spike-wave activation seen in slow-wave sleep<sup>[22]</sup>. Furthermore, few genetic causes of ESES/CSWS/epilepsy aphasia spectrum have been reported, where the common underlying pathway is channelopathy<sup>[23]</sup>. The different forms of seizures in EAS include partial seizure, generalized tonic-clonic seizure, atypical absence seizure, myoclonic seizure, atonic seizure, etc. Aphasia can occur before or after epilepsy. Moreover, 70% of patients with epilepsy-aphasia syndrome have epileptic seizures with EEG features that reveal spike-and-wave patterns in the unilateral or bitemporal lobes during the waking period.



**Figure 2** Gene sequences of three members in the family. A: *De novo* mutation of the *CNKSR2* gene (*c. 2185C>T*, *p.Arg729Ter*) in the patient; B, C: No mutation was observed at the same locus in the parents (arrows).

Generalized continuous spike-and-wave is seen in all leads during sleep, and bilateral synchronous discharge accounts for more than 85% of stage in abnormal discharge<sup>[1]</sup>. The other 30% of children do not seizures, but show EEG abnormalities (which does not meet the EEG standards of CSWS). Their EEG's showed the following during sleep: Induced focal epileptiform discharges were identified mainly at the center (but may also might be involved in other areas); or there was no bilateral synchronous

activity; or synchronous activity accounted for less than 85% of NREM (non-rapid eye movement) sleep. These cases are all called intermediate epilepsy aphasia (IEADs). The speech recovery ability of IEADs patients is better than that of EAS.

Patients with epilepsy and speech disorders should be advised to undergo EEG monitoring and genetic testing to confirm the diagnosis. Currently, there are no specific medications for the treatment of X-linked epile-





**Figure 3** Secondary structures of wild-type and mutated *CNKS2* proteins predicted by PSIPRED. A: The wild-type *CNKS2* gene encodes an intact peptide chain of 1034 amino acids; B: The mutated *CNKS2* gene leads to an early termination of the synthesis of the peptide chain and only No.1-728 amino acids are expressed.


psy-aphasia syndrome. The early diagnosis and early use of antiepileptic drugs as well as hormone therapy can recover speech comprehension to different degrees and improve abnormal discharge. Therefore, the overall prognosis of patients is good. Clinical seizures should be treated with antiseizure drugs, and barbiturates, carbamazepine, and phenytoin should be avoided as they can potentiate spike wave discharges during sleep<sup>[24,25]</sup>. Although there is evidence that mutations or deletions of *CNKS2* lead to neurological development defects, such as epilepsy and intellectual disability, the pathogenesis remains unclear. Therefore, the next step is to screen a large number of epileptic encephalopathy individuals to

delineate the phenotypic spectrum of the *CNKS2* mutation. Second-generation gene sequencing can assist in the identification of hereditary etiology and discovery of new mutations while expanding on the early epilepsy encephalopathy clinical phenotype and genetic spectrum. Simultaneously, the pathogenesis of X-linked epilepsy-aphasia syndrome should be studied to assist clinicians in diagnosis and genetic counseling.

## ARTICLE HIGHLIGHTS

### Case characteristics

Before experiencing seizures, our patient suffered from developmental de-



**Figure 4** Tertiary structures of wild-type and mutated *CNKSR2* proteins predicted by RaptorX. The spatial structures of *CNKSR2* proteins are significantly different between the wild-type (A) and the patient (B).

lays and attention deficit hyperactivity disorder, which is consistent with the performance of X-linked intellectual disability. After seizure occurrence, the patients' speech expression gradually decreased, the electroencephalogram (EEG) continued to show abnormal wave patterns during sleep, and a *de novo* mutation of the *CNKSR2* gene was identified.

### Clinical diagnosis

X-linked epilepsy-aphasia syndrome.

### Differential diagnosis

Hysteria and childhood autism.

### Laboratory diagnosis

A *de novo* mutation of the *CNKSR2* gene.

### Imaging diagnosis

EEG continued to show abnormal wave patterns during sleep.

### Treatment

Immunoglobulin, oral prednisone, lamotrigine and sodium valproate oral solution.

### Related reports

Frequency of *CNKSR2* mutation in the X-linked epilepsy-aphasia spectrum has been reported in the journal of *Epilepsia*.

### Term explanation

Epileptic encephalopathy with continuous spike-and-wave during sleep.

### Experiences and lessons

This case will contribute to improvements in our understanding of X-linked epilepsy-aphasia syndrome. Patients with epilepsy and speech disorders should be advised to undergo EEG monitoring and genetic testing to confirm the diagnosis. The early diagnosis and early use of antiepileptic drugs as well as hormone therapy can recover speech comprehension to different degrees and improve abnormal discharge.

## ACKNOWLEDGMENTS

We are grateful to the patient for allowing us to publish this information.

## REFERENCES

1 Tsai MH, Vears DF, Turner SJ, Smith RL, Berkovic SF, Sadleir

- LG, Scheffer IE. Clinical genetic study of the epilepsy-aphasia spectrum. *Epilepsia* 2013; **54**: 280-287 [PMID: 23294109 DOI: 10.1111/epi.12065]
- 2 Damiano JA, Burgess R, Kivity S, Lerman-Sagie T, Afawi Z, Scheffer IE, Berkovic SF, Hildebrand MS. Frequency of *CNKSR2* mutation in the X-linked epilepsy-aphasia spectrum. *Epilepsia* 2017; **58**: e40-e43 [PMID: 28098945 DOI: 10.1111/epi.13666]
- 3 Therrien M, Wong AM, Rubin GM. CNK, a RAF-binding multidomain protein required for RAS signaling. *Cell* 1998; **95**: 343-353 [PMID: 9814705 DOI: 10.1016/S0092-8674(00)81766-3]
- 4 Nagase T, Ishikawa K, Suyama M, Kikuno R, Hirotsawa M, Miyajima N, Tanaka A, Kotani H, Nomura N, Ohara O. Prediction of the coding sequences of unidentified human genes. XII. The complete sequences of 100 new cDNA clones from brain which code for large proteins in vitro. *DNA Res* 1998; **5**: 355-364 [PMID: 10048485]
- 5 Vaags AK, Bowdin S, Smith ML, Gilbert-Dussardier B, Brocke-Holmeffjord KS, Sinopoli K, Gilles C, Haaland TB, Vincent-Delorme C, Lagrue E, Harbuz R, Walker S, Marshall CR, Houge G, Kalscheuer VM, Scherer SW, Minassian BA. Absent *CNKSR2* causes seizures and intellectual, attention, and language deficits. *Ann Neurol* 2014; **76**: 758-764 [PMID: 25223753 DOI: 10.1002/ana.24274]
- 6 Aypar U, Wirrell EC, Hoppman NL. *CNKSR2* deletions: a novel cause of X-linked intellectual disability and seizures. *Am J Med Genet A* 2015; **167**: 1668-1670 [PMID: 25754917 DOI: 10.1002/ajmg.a.36902]
- 7 Houge G, Rasmussen IH, Hovland R. Loss-of-Function *CNKSR2* Mutation Is a Likely Cause of Non-Syndromic X-Linked Intellectual Disability. *Mol Syndromol* 2012; **2**: 60-63 [PMID: 22511892 DOI: 10.1159/000335159]
- 8 Hu H, Haas SA, Chelly J, Van Esch H, Raynaud M, de Brouwer AP, Weinert S, Froyen G, Frints SG, Laumonnier F, Zemojtel T, Love MI, Richard H, Emde AK, Bienek M, Jensen C, Hambrock M, Fischer U, Langnick C, Feldkamp M, Wissink-Lindhout W, Lebrun N, Castelnau L, Rucci J, Montjean R, Dorseuil O, Billuart P, Stuhlmann T, Shaw M, Corbett MA, Gardner A, Willis-Owen S, Tan C, Friend KL, Belet S, van Roozendaal KE, Jimenez-Pocquet M, Moizard MP, Ronce N, Sun R, O'Keeffe S, Chenna R, van Bömmel A, Göke J, Hackett A, Field M, Christie L, Boyle J, Haan E, Nelson J, Turner G, Baynam G, Gillissen-Kaesbach G, Müller U, Steinberger D, Budny B, Badura-Stronka M, Latos-Bieleńska A, Ousager LB, Wieacker P, Rodríguez Criado G, Bondeson ML, Annerén G, Dufke A, Cohen M, Van Maldergem L, Vincent-Delorme C, Echenne B, Simon-Bouy B, Kleefstra T, Willemsen M, Fryns JP, Devriendt K, Ullmann R, Vingron M, Wrogemann K, Wienker TF, Tzschach A, van Bokhoven H, Gecz J, Jentsch TJ, Chen W, Ropers HH, Kalscheuer VM. X-exome sequencing of 405 unresolved families identifies seven novel intellectual disability genes. *Mol Psychiatry* 2016; **21**: 133-148 [PMID: 25644381 DOI: 10.1038/mp.2015.111]

- 10.1038/mp.2014.193]
- 9 **Piton A**, Redin C, Mandel JL. XLID-causing mutations and associated genes challenged in light of data from large-scale human exome sequencing. *Am J Hum Genet* 2013; **93**: 368-383 [PMID: 23871722 DOI: 10.1016/j.ajhg.2013.06.013]
- 10 **Buchan DW**, Minneci F, Nugent TC, Bryson K, Jones DT. Scalable web services for the PSIPRED Protein Analysis Workbench. *Nucleic Acids Res* 2013; **41**: W349-W357 [PMID: 23748958 DOI: 10.1093/nar/gkt381]
- 11 **Källberg M**, Wang H, Wang S, Peng J, Wang Z, Lu H, Xu J. Template-based protein structure modeling using the RaptorX web server. *Nat Protoc* 2012; **7**: 1511-1522 [PMID: 22814390 DOI: 10.1038/nprot.2012.085]
- 12 **Ma J**, Wang S, Zhao F, Xu J. Protein threading using context-specific alignment potential. *Bioinformatics* 2013; **29**: i257-i265 [PMID: 23812991 DOI: 10.1093/bioinformatics/btt210]
- 13 **Peng J**, Xu J. RaptorX: exploiting structure information for protein alignment by statistical inference. *Proteins* 2011; **79** Suppl 10: 161-171 [PMID: 21987485 DOI: 10.1002/prot.23175]
- 14 **Yao I**, Ohtsuka T, Kawabe H, Matsuura Y, Takai Y, Hata Y. Association of membrane-associated guanylate kinase-interacting protein-1 with Raf-1. *Biochem Biophys Res Commun* 2000; **270**: 538-542 [PMID: 10753660 DOI: 10.1006/bbrc.2000.2475]
- 15 **Addis L**, Virdee JK, Vidler LR, Collier DA, Pal DK, Ursu D. Epilepsy-associated GRIN2A mutations reduce NMDA receptor trafficking and agonist potency - molecular profiling and functional rescue. *Sci Rep* 2017; **7**: 66 [PMID: 28242877 DOI: 10.1038/s41598-017-00115-w]
- 16 **Yang X**, Qian P, Xu X, Liu X, Wu X, Zhang Y, Yang Z. GRIN2A mutations in epilepsy-aphasia spectrum disorders. *Brain Dev* 2018; **40**: 205-210 [PMID: 29056244 DOI: 10.1016/j.braindev.2017.09.007]
- 17 **Carvill GL**, Regan BM, Yendle SC, O'Roak BJ, Lozovaya N, Bruneau N, Burnashev N, Khan A, Cook J, Geraghty E, Sadleir LG, Turner SJ, Tsai MH, Webster R, Ouvrier R, Damiano JA, Berkovic SF, Shendure J, Hildebrand MS, Szepietowski P, Scheff-er IE, Mefford HC. GRIN2A mutations cause epilepsy-aphasia spectrum disorders. *Nat Genet* 2013; **45**: 1073-1076 [PMID: 23933818 DOI: 10.1038/ng.2727]
- 18 **Kelemen A**, Barsi P, Gyorsok Z, Sarac J, Szucs A, Halász P. Thalamic lesion and epilepsy with generalized seizures, ESES and spike-wave paroxysms--report of three cases. *Seizure* 2006; **15**: 454-458 [PMID: 16828318 DOI: 10.1016/j.seizure.2006.05.006]
- 19 **Hu LY**, Shi XY, Feng C, Wang JW, Yang G, Lammers SH, Yang XF, Ebrahimi-Fakhari D, Zou LP. An 8-year old boy with continuous spikes and waves during slow sleep presenting with positive onconeural antibodies. *Eur J Paediatr Neurol* 2015; **19**: 257-261 [PMID: 25596064 DOI: 10.1016/j.ejpn.2014.12.012]
- 20 **Connolly AM**, Chez MG, Pestronk A, Arnold ST, Mehta S, Deuel RK. Serum autoantibodies to brain in Landau-Kleffner variant, autism, and other neurologic disorders. *J Pediatr* 1999; **134**: 607-613 [PMID: 10228297 DOI: 10.1016/S0022-3476(99)70248-9]
- 21 **van den Munckhof B**, de Vries EE, Braun KP, Boss HM, Willemsen MA, van Royen-Kerkhof A, de Jager W, Jansen FE. Serum inflammatory mediators correlate with disease activity in electrical status epilepticus in sleep (ESES) syndrome. *Epilepsia* 2016; **57**: e45-e50 [PMID: 26666401 DOI: 10.1111/epi.13274]
- 22 **Stephani U**, Carlsson G. The spectrum from BCECTS to LKS: The Rolandic EEG trait-impact on cognition. *Epilepsia* 2006; **47** Suppl 2: 67-70 [PMID: 17105466 DOI: 10.1111/j.1528-1167.2006.00694.x]
- 23 **Kessi M**, Peng J, Yang L, Xiong J, Duan H, Pang N, Yin F. Genetic etiologies of the electrical status epilepticus during slow wave sleep: systematic review. *BMC Genet* 2018; **19**: 40 [PMID: 29976148 DOI: 10.1186/s12863-018-0628-5]
- 24 **Fine AL**, Wong-Kissel LC, Wirrell EC. A Novel Phenotype in a Previously Described Epilepsy-Aphasia Disorder. *Semin Pediatr Neurol* 2018; **26**: 21-24 [PMID: 29961510 DOI: 10.1016/j.spen.2018.04.004]
- 25 **Striano P**, Capovilla G. Epileptic encephalopathy with continuous spikes and waves during sleep. *Curr Neurol Neurosci Rep* 2013; **13**: 360 [PMID: 23666433 DOI: 10.1007/s11910-013-0360-5]

**P- Reviewer:** Garg RK, Kai K, Razek AAKA, Takahashi H

**S- Editor:** Ji FF **L- Editor:** A **E- Editor:** Tan WW





Published by **Baishideng Publishing Group Inc**  
7901 Stoneridge Drive, Suite 501, Pleasanton, CA 94588, USA  
Telephone: +1-925-223-8242  
Fax: +1-925-223-8243  
E-mail: [bpgoffice@wjgnet.com](mailto:bpgoffice@wjgnet.com)  
Help Desk: <http://www.f6publishing.com/helpdesk>  
<http://www.wjgnet.com>

